Lisa A. Jackson, MD, MPH

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Lisa.A.Jackson@kp.org

Curriculum vitae (CV)

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia

Recent publications

Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, Williams JTB, Naleway AL, Klein NP, Hambidge SJ, Jacobsen SJ, Glanz JM, Jackson LA, Shimabukuro TT, Weintraub ES. SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020 MMWR Morb Mortal Wkly Rep. 2020;69(38):1355-1359. doi: 10.15585/mmwr.mm6938e2. PubMed

Jackson LA, Roberts PC, Graham BS A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply 2020 Sep 17;383(12):1191-1192. doi: 10.1056/NEJMc2026616. Epub 2020-08-19. PubMed

Hesse EM, Navarro RA, Daley MF, Getahun D, Henninger ML, Jackson LA, Nordin J, Olson SC, Zerbo O, Zheng C, Duffy J Risk for Subdeltoid Bursitis After Influenza Vaccination: A Population-Based Cohort Study 2020 Aug 18;173(4):253-261. doi: 10.7326/M19-3176. Epub 2020-06-23. PubMed

Munoz FM, Patel SM, Jackson LA, Swamy GK, Edwards KM, Frey SE, Petrie CR, Sendra EA, Keitel WA Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants 2020 Jul 14;38(33):5355-5363. doi: 10.1016/j.vaccine.2020.05.059. Epub 2020-06-19. PubMed

Chung JR, Flannery B, Gaglani M, Smith ME, Reis EC, Hickey RW, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Segaloff HE, Kim SS, Patel MM Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness 2020 Jul;174(7):705-713. doi: 10.1001/jamapediatrics.2020.0372. PubMed

Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Dunnigan K, Foust A, Sessions W, DaSilva J, Le S, Stark T, Kondor RJ, Barnes JR, Wentworth DE, Brammer L, Fry AM, Patel MM, Flannery B Interim Estimates of 2019-20 Seasonal Influenza Vaccine Effectiveness - United States, February 2020 2020 Feb 21;69(7):177-182. doi: 10.15585/mmwr.mm6907a1. Epub 2020-02-21. PubMed

Anderson EJ, Lai L, Wrammert J, Kabbani S, Xu Y, Priyamvada L, Hill H, Goll JB, Jensen TL, Kao C, Yildirim I, Rouphael N, Jackson L, Mulligan MJ Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine 2020 Feb 6;8(1). doi: 10.3390/vaccines8010069. Epub 2020-02-06. PubMed

Yu W, Zheng C, Xie F, Chen W, Mercado C, Sy LS, Qian L, Glenn S, Tseng HF, Lee G, Duffy J, McNeil MM, Daley MF, Crane B, McLean HQ, Jackson LA, Jacobsen SJ The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the Vaccine Safety Datalink 2020 Feb;29(2):182-188. doi: 10.1002/pds.4919. Epub 2019-12-03. PubMed

Flannery B, Kondor RJG, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Belongia EA, McLean HQ, Kim SS, Blanton L, Kniss K, Budd AP, Brammer L, Stark TJ, Barnes JR, Wentworth DE, Fry AM, Patel M Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season 2020 Jan;221(1):8-15. doi: 10.1093/infdis/jiz543. PubMed

Ahmed F, Kim S, Nowalk MP, King JP, VanWormer JJ, Gaglani M, Zimmerman RK, Bear T, Jackson ML, Jackson LA, Martin E, Cheng C, Flannery B, Chung JR, Uzicanin A Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018 2020 Jan;26(1). doi: 10.3201/eid2601.190743. PubMed